|
|
|
| Preparation and Biological Activity of Anti-Her2 Antibody-MMAE Conjugate |
| SHE Dong-yu, HUANG Jia-hui, LIU Dong-chen, ZHANG Tu, XIE Qiu-ling |
| College of Life Science and Technology, Guangdong Provincial Key Laboratory of Bioengineering Medicine, National Engineering Research Center of Genetic Medicine, Jinan University, Guangzhou 510632, China |
|
|
|
Abstract Object: To prepare an antibody drug conjugate (ADC) with Her2 antibody and MMAE. And to test the effect of this ADC on growth, apoptosis and cell cycle of breast cancer cell. Method: Anti-Her2 monoclonal antibody PH was conjugated with MMAE by a linker. The effect of ADC on tumor cell was compared with Her2 antibody in vitro. Results: The conjugating rate was about 80% under the optimized condition. It was shown that this ADC has higher ability than Her2 antibody for inhibiting growth of breast cancer cells, whether with high Her2 expression or low Her2 expression. And this ADC could induced cell apoptosis up to 40 percents, while PH only to 20 percents. Conclusion: The anti-Her2 antibody-MMAE conjugate has higher activity to inhibit cancer cell than Her2 antibody.
|
|
Received: 15 December 2014
Published: 25 February 2015
|
|
|
|
|
|
[1] Carter P J. Introduction to current and future protein therapeutics: a protein engineering perspective. Experimental Cell Research, 2011, 317(9): 1261-1269.
[2] Scott A M, Wolchok J D, Old L J. Antibody therapy of cancer. Nature Reviews Cancer, 2012, 12(4): 278-287.
[3] Sapra P, Hooper A T, O'Donnell C J, et al. Investigational antibody drugconjugates for solid tumors. Expert Opinion on Investigational Drugs, 2011, 20(8): 1131-1149.
[4] Junttila T T, Li G, Parsons K, et al. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Research and Treatment, 2011, 128(2): 347-356.
[5] Wu A M, Senter P D. Arming antibodies: prospects and challenges for immunoconjugates. Nature Biotechnology, 2005, 23(9): 1137-1146.
[6] Bradley A M, Devine M, DeRemer D. Brentuximab vedotin: An anti-CD30 antibody-drug conjugate. American Journal of Health-System Pharmacy, 2013, 70(7): 589-597.
[7] Gerber H P, Koehn F E, Abraham R T. The antibody-drug conjugate: an enabling modality fornatural product-based cancer therapeutics.Natural Product Reports, 2013, 30(5): 625-639.
[8] Sun M M C, Beam K S, Cerveny C G, et al. Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconjugate Chemistry, 2005, 16(5): 1282-1290.
[9] Wagner-Rousset E, Janin-Bussat M C, Colas O, et al. Antibody-drug conjugate model fast characterization by LC-MS following IdeS proteolytic digestion
[C]//MAbs. Landes Bioscience, 2014, 6(1): 173.
[10] Zein N, Poncin M, Nilakantan R, et al. Calicheamicin gamma 1I and DNA: molecular recognition process responsible for site-specificity. Science, 1989, 244(4905): 697-699.
[11] Hamblett K J, Senter P D, Chace D F, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clinical Cancer Research, 2004, 10(20): 7063-7070.
[12] Mandelbaum-Shavit F, Wolpert-DeFilippes M K, Johns D G. Binding of maytansine to rat brain tubulin. Biochemical and Biophysical Research Communications, 1976, 72(1): 47-54.
[13] Sapra P, Hooper A T, O'Donnell C J, et al. Investigational antibody drug conjugates for solid tumors. Expert Opinion on Investigational Drugs, 2011, 20(8): 1131-1149.
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
